



I hereby certify that this correspondence is being deposited with the United States Patent Service as first class mail in an envelope addressed to:

Attorney D

Client Ref No.: 09854356-1

Assistant Commissioner for Patents
Washington, D.C. 20231

On December 12, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Lawanna J. Bauld

RECEIVED

DEC 23 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CHEEVER et al.

Application No.: 09/854,356

Filed: May 9, 2001

For: HER-2/NEU FUSION PROTEINS

Examiner: Yu Misook

Art Unit: 1646

RESPONSE TO RESTRICTION
REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the restriction requirement mailed September 9, 2002, please amend the above-identified application as follows. A petition to extend the time for response for three months, from October 9, 2002 to January 9, 2003, is submitted herewith.

IN THE SPECIFICATION

Please amend the specification on page 52, lines 4-10, as follows:

Other preferred adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), Detox (Corixa Corporation, Hamilton, MT), RC-529 (Corixa, USA) and Aminoalkyl glucosaminide 4-phosphates (AGPs).